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Abstract
Background: Healthcare-associated infections (HCAI) represent up to 50 % of all infections among patients
admitted from the community. The current review intends to provide a systematic review on the microbiological
profile involved in HCAI, to compare it with community-acquired (CAI) and hospital-acquired infections (HAI) and
to evaluate the definition accuracy to predict infection by potentially drug resistant pathogens.
Methods: We search for HCAI in MEDLINE, SCOPUS and ISI Web of Knowledge with no limitations in regards
to publication language, date of publication, study design or study quality. Only studies using the definition by
Friedman et al. were included. This review was registered at PROSPERO Systematic Review Registration with the
Number CRD42014013648.
Results: A total of 21 eligible studies with 12,096 infected patients were reviewed; of these 3497 had HCAI,
2723 were microbiologically documented. Twelve studies were on pneumonia involving 1051 patients with
microbiological documented HCAI, the application of the current guidelines for this group of patients would
result in an appropriate antibiotic therapy in 95 % of cases at the expense of overtreatment in 73 %; the application
of community-acquired pneumonia guidelines would be adequate in only 73–76 % of the cases; an alternative
regimen with piperacillin-tazobactam or aztreonam plus azithromycin would increase antibiotic adequacy rate
to 90 %. Few studies were found on additional focus of infection: endocarditis, urinary, intra-abdominal and
bloodstream infections. All studies included in this review showed an association of the HCAI definition with
infection by PDR pathogens when compared to CAI [odds ratio (OR) 4.05, 95 % confidence interval (95 % CI)
2.60–6.31)]. The sensitivity of HCAI to predict infection by a PDR pathogen was 0.69 (0.65–0.72), specificity was
0.67 (0.66–0.68), positive likelihood ratio was 1.9 and the area under the summary ROC curve was 0.71.
Conclusions: This systematic review provides evidence that HCAI represents a separate group of infections in terms
of the microbiology profile, including a significant association with infection by PDR pathogens, for the main focus
of infection. The results provided can help clinician in the selection of empiric antibiotic therapy and international
societies in the development of specific treatment recommendations.
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Background
The concept of healthcare-associated infections (HCAI)
was proposed in 2002 as a new category to fill the gap
between community (CAI) and hospital-acquired in-
fections (HAI) [1, 2]. Since then a broad range of
definitions have been used with the definition origin-
ally proposed by Friedman et al. [1] being the most
commonly used in clinical studies on HCAI [3] - an
infection present at hospital admission or within 48 h
of admission in patients that fulfilled any of the fol-
lowing criteria:
* received intravenous therapy at home, wound care or
specialized nursing care through a healthcare agency,
family or friends; or had self-administered intravenous
medical therapy in the 30 days before the infection.
Patients whose only home therapy was oxygen use
were excluded;
* attended a hospital or hemodialysis clinic or received
intravenous chemotherapy in the previous 30 days;
* were hospitalized in an acute care hospital for two or
more days in the previous 90 days,
* resided in a nursing home or long-term care facility.
Patients with HCAI can represent up to 50 % of all
infected patients admitted from the community setting
[1, 4–10] and are clearly a growing class due to the
increasing age of patients, as this means they have more
chronic diseases, require more medical and surgical
interventions, are consequently more frequently hospi-
talized and institutionalized and are thus more at risk of
colonization of and infection by multidrug resistant
pathogens [11]. Nearly half of all HCAI patients receive
antibiotic therapy according to international guidelines
for community-acquired infections, with associated high
rates of inadequate antibiotic therapy among them [12].
In 2005, the ATS/IDSA recommended a treatment
for healthcare associated pneumonia (HCAP) similar
to hospital-acquired pneumonia [13], but accumulating
evidence suggests that such a broad spectrum antibiotic
therapy approach might not be necessary and probably
should be avoided in order to prevent the inherent devel-
opment of resistances [14].
The absence of a unique and consensual definition has
led to contradictory results and increasing controversy
around the utility of the HCAI concept [15, 16]; the
inclusion of different populations lead to different results
in microbiology profiles and in multidrug resistant path-
ogens prevalence. An analysis on the utility of the HCAI
concept restricted to a single definition would be helpful
to clarify this controversy.
The current review, restricted to all studies that used
the definition proposed by Friedman et al. [1], intends
to provide a systematic review on the microbiological
profile involved in HCAI, to compare it with CAI and
HAI and to evaluate the definition accuracy to predict
infection by potentially drug resistant pathogens.
Methods
A systematic review in accordance with PRISMA State-
ment was conducted. Objectives and methods of the
study were specified in advance and documented in a
protocol. This systematic review was registered at
PROSPERO Systematic Review Registration with the
Number CRD42014013648.
The search was performed in accordance with the
recommendations of the Cochrane collaboration, using
MEDLINE/PubMed, SCOPUS and ISI Web of Know-
ledge, with the earliest achievable dating until January
2014. A manual search of references from reports, earl-
ier reviews and retrieved studies was also performed.
Books of abstracts and CD-ROMs from several annual
scientific meetings were searched for relevant abstracts
(Fig. 1). No language restrictions were applied and papers
written in foreign languages were translated.
The electronic search strategy covered the main subject
area: healthcare-associated infections (Additional file 1).
The last search was performed on January 17th 2014.
The inclusion criteria were all studies (excluding case
series/reports) on adult patients admitted to hospital
that used the definition of HCAI from Friedman et al.
[1] and provided microbiology results by focus of infec-
tion, comparing with CAI and/or HAI.
The following classification of infection according to
place of acquisition was used:
– CAI - infection detected within 48 h of hospital
admission in patients without previous contact with
healthcare services.
– HAI - localised or systemic condition: 1) that results
from adverse reaction to the presence of an
infectious agent(s) or its toxin(s) and 2) that was
present 48 h or more after hospital admission and
not incubating at hospital admission time [17].
– HCAI was defined according to the criteria
proposed by Friedman et al. [1].
Potentially drug resistant (PDR) pathogens were defined
as methicillin-resistant Staphylococcus aureus, Pseudo-
monas sp, Acinectobacter sp, Stenotrophomonas maltophi-
lia and extended-spectrum beta-lactamases gram negative
producers (ESBL) because these are usually not covered
by the antibiotic therapy recommended for community-
acquired infections [18–20].
The results of the literature search were accessed by
two reviewers (TC, MA) and non-relevant studies, based
on title and abstract, were excluded. For potentially
relevant studies, the full text was obtained, and two
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investigators (TC, MA) independently assessed study
eligibility and extracted data on study design, objectives
of the included studies, microbiological profile by focus
of infection and place of acquisition (HCAI, CAI and
HAI) using a data extraction protocol; disagreements
were resolved through consultation with a third reviewer
(LA).
Each selected study was independently evaluated by
two reviewers (TC, MA) in terms of strength of evidence
through examination of the study design and quality of
data.
Potential threats to the internal validity of included
studies were evaluated considering the following cri-
teria [21]:
– The authors define inclusion criteria;
– The authors define an adequate selection method
(for instance, all hospitalized patients with
infection);
– The selection of participants was consecutive;
– The outcome data was complete (microbiology data
by place of acquisition) and reported (no attrition
bias);
– All results were reported (reporting bias).
Studies that met all of the five criteria above were
classified as “low risk of bias”. Studies that met one or
more criteria only partially were classified as “moderate
risk of bias”. Studies where one or more of these criteria
was not met were classified as “high risk of bias”.
Detailed data on individual studies included in this
review are provided in Additional file 2: Table S1. Data
from the study by Cardoso et al. [22] is split in four
components (respiratory, urinary, intra-abdominal and
bloodstream infections), in order to facilitate microbiol-
ogy profile interpretation and synthesis.
Odds ratios (ORs) comparing the incidence of PDR
pathogens in HCAI vs CAI were calculated. Odds ratios
were then pooled using a Mantel-Haenszel random
effects model [23]. The sensitivity and specificity of the
HCAI definition to predict infection by a PDR pathogen
were calculated and the discriminative power studied
through the analysis of the area under the summary
receiver operator characteristics (sROC) curve [24]. Stat-
istical heterogeneity was assessed using the Higgins I2
tests. Publication bias was assessed through the ana-
lysis of the funnel plot. Analyses were conducted using
SPSS version 20, Review Manager 5 and Meta-DiSc
for Windows.
Fig. 1 Selection of reports included in the analysis
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Results
The search retrieved a total of 54,231 references, among
which 15,413 duplicates were identified. Of the 38,818
remaining articles, 38,486 were excluded based on title
and abstract evaluation (Fig. 1). Full texts were obtained
for the remaining 332 articles. Of these, 118 were review
articles or opinion pieces (narrative reviews, commentar-
ies and letters), 193 did not meet the inclusion criteria
and 21 studies were included.
The description of the included studies by focus and
place of acquisition of infection is shown in Additional file
2: Table S1, namely: pneumonia (Additional file 2: Table
S1a), endocarditis (Additional file 2: Table S1b), urinary
tract (Additional file 2: Table S1c), intra-abdominal
(Additional file 2: Table S1d) and bloodstream infec-
tions (Additional file 2: Table S1e).
The 21 studies included for microbiology analysis
involved a total of 12,096 patients of whom 3497 had
HCAI, that in 2723 (78 % of cases) were microbiologic-
ally documented. Patients with HCAI represented 34 %
of all patients admitted from the community (3497 among
10,300 patients). All studies included in the review show
an association of HCAI with infection by a PDR pathogen
that was significant in 15 (63 %) (Fig. 2). The pooled OR
(95 % CI) was 4.09 (2.62–6.37), with significant heterogen-
eity (I2 = 79 %, p < 0.0001).
Pneumonia
Healthcare-associated pneumonia (HCAP) was charac-
terised in 1814 patients and of those 1051 had microbio-
logical documentation (58 %) (Table 1): Pseudomonas
aeruginosa was isolated in 102 (10 %), MRSA were
isolated in 75 (7 %), ESBL strains in 18 (2 %), Acinec-
tobacter spp in 8 (0.8 %) and Stenotrophomonas mal-
tophilia in 6 (0.6 %) patients. In 129 (12.3 %) cases
the authors did not specify the infectious agent.
The prevalence of PDR pathogens was 21 % (n = 219)
in HCAP, compared to 5 % (n = 119) in CAP (p < 0.001)
and 46 % (n = 56) in HAP (p < 0.001). All studies show
the association of HCAP with infection by a PDR patho-
gen (Fig. 3), that is significant in 10 (77 %). The pooled
OR (95 % CI) was 3.88 (2.35–6.43), with high heterogen-
eity (I2 = 67 %, p = 0.003).
European studies [10, 22, 25–27], included 3894 pa-
tients: 815 in the HCAP group with an isolation rate of
83 % (n = 679), 2878 in the CAP group with an isolation
rate of 60 % (n = 1732) and 147 in the HAP group with
an isolation rate of 82 % (n = 121). The prevalence of
PDR pathogens was 5 % (n = 37) in HCAP, compared to
2 % (n = 33) in CAP (p < 0.001) and 46 % (n = 56) in
HAP (p < 0.001). The pooled OR (95 % CI) for infection
by a PDR organism in the HCAP group was 4.16 (1.25–
13.82), with important heterogeneity (I2 = 77 %, p = 0.001)
(Fig. 3).
The remaining eight studies were from Asia and
included 2331 patients: 945 in the HCAP group with an
isolation rate of 57 % (n = 535) and 1386 in the CAP
group with an isolation rate of 45 % (n = 625). The
prevalence of PDR pathogens was 34 % (n = 182) in
HCAP and 14 % (n = 86) in CAP (p < 0.001). The pooled
OR (95 % CI) for association of HCAP and infection by
a PDR pathogen was 3.75 (2.16–6.51), again with an
important heterogeneity (I2 = 63 %, p = 0.009) (Fig. 3).
Focusing only in “low risk of bias” studies, seven stud-
ies including 4522 patients were analysed: 1120 in the
HCAP group with an isolation rate of 68 % and 3297 in
the CAP group with an isolation rate of 60 %, the preva-
lence of different microorganisms remained the same
(with a maximum variation of 2 % in each), with the
exception of PDR pathogens prevalence that decreased
to 18 %, probably due to the higher rate of overall isola-
tion. In this group six out of the seven studies showed a
significant association of HCAP with infection by a PDR
pathogen. The pooled OR (95 % CI) for infection by a
PDR in the HCAP group was 5.35 (2.44–11.75), with
I2 = 78 % (p = 0.0002).
The ATS/IDSA guidelines for the treatment of
community-acquired pneumonia [18] recommend cefo-
taxime, ceftriaxone or ampicillin/sulbactam plus azi-
thromycin or monotherapy with a fluroquinolone as
an empirical antibiotic therapy. Considering only the
species described among all isolations in HCAP (941
out of 1058), 711 (76 %) of the patients with HCAP
would receive appropriate antibiotic therapy if the anti-
biotic therapy option is a fluroquinolone or a 3rd gener-
ation cephalosporins plus macrolide, if a beta-lactamic plus
azithromycin was to be given the number would decrease
to 691 (73 %) due to some gram negative uncovering.
The ATS/IDSA guidelines for the treatment of
healthcare-associated pneumonia and hospital-acquired
pneumonia [13] recommend as an empirical antibiotic
therapy: cefepime, ceftazidime, imipenem, meropenem or
piperacillin-tazobactam plus ciprofloxacin, levofloxacin,
amikacin, gentamicin or tobramycin plus linezolid or
vancomycin. If these recommendations are applied to the
group of 941 patients included in this review, with micro-
biologically documented HCAP and infectious agent
specified, 894 (95 %) would receive appropriate antibiotic
therapy. Patients with Acinectobater spp. (n = 8) would
only be covered if the isolated rods are sensitive, ESBL
(n = 18) strains only if carbapenems are used and atyp-
ical agents (n = 38) if a fluroquinolone is given. Steno-
trophomonas spp. (n = 6) and fungi (n = 3) would be
left out regardless of either option. The use of these
guidelines would result in overtreatment of at least
691 patients (73 %).
If piperacillin-tazobactam or aztreonam plus azithro-
mycin were used to treat the same group of HCAP
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patients the rate for an appropriate antibiotic therapy
would increase to 90 % (n = 843).
Other foci of infection
There were only two studies on endocarditis: a small
single centre study at an oncology department classified
as “moderate risk of bias” [28] and a large, single centre,
“low risk of bias” study [5] and both found significant
differences in the microbiological profile between HCAI,
CAI and HAI, particularly regarding the prevalence of
PDR pathogens (Additional file 2: Table S1b, Table 1 and
Fig. 2).
Fig. 2 Association of healthcare-associated infection with infection by potentially drug resistant pathogens. Association of healthcare-associated
infection with infection by potentially drug resistant pathogens when compared with community-acquired infection, for the main focus of infection.
Abbreviations: CAI, community-acquired infection; HCAI, healthcare-associated infection; UTI, urinary tract infection; BSI, bloodstream infection;
IAI, intra-abdominal infection; CI, confidence interval; M-H, Maentel-Haentzel; BSI, bloodstream infections
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Table 1 Microbiological profile of healthcare-associated, community and hospital-acquired infections by focus of infection
Pneumonia Endocarditis
Number of studies/patients 13 studies/6154 patients Number of studies/patients 2 studies/1814 patients
Number of patients
(isolations)
HCAI - 1814 (1051–58 %) CAI - 4264 (2355–55 %) HAI - 147 (121–82 %) Number of patients (isolations) HCAI 284 (100 %) CAI 1213 (100 %) HAI 325 (100 %)
Microorganism, n (%) Microorganism, n (%)
Streptococcus pneumoniae 394 (37) 1389 (59) 18 (15) Staphylococci 164 (59) 285 (24) 124 (38)
Klebsiella pneumoniae 114 (11) 70 (3) 6 (5) MRSA (of all Staphylococci isolation) 89 (54) 39 (14) 58 (47)
Staphylococcus aureus 124 (12) 106 (4) 31 (26) Enterococci 45 (16) 97 (8) 43 (13)
MRSA (of all Staphylococci
isolation)
75 (60) 31 (29) 19 (61) Coagulase negative Staphylococci 38 (14) 71 (6) 39 (12)
Pseudomonas aeruginosa 102 (10) 69 (3) 27 (22) Streptococcus viridans 36 (13) 328 (27) 14 (4)
Haemophilus influenzae 56 (5) 179 (8) 1 (1) Gram negative bacilli 0 (0) 2 (0.2) 1 (0.3)
Atypical agents 38 (4) 349 (15)
E. coli 18 (2) 6 (0.3) 7 (6)
PDR pathogensa, p value* 235 (22) 119 (5), p < 0.0001 56 (46), p < 0.0001 PDR pathogensa, p value* 89 (32) 40 (3), p < 0.0001 58 (18), p < 0.0001
Urinary tract infections Bloodstream infection
Number of studies/patients 2 studies/595 patients Number of studies/patients 6 studies/3320 patients
Number of patients
(isolations)
HCAI 199 (189–95 %) CAI 228 (205–90 %) HAI 168 (163–97 %) Number of patients HCAI 1176 CAI 994 HAI 1337
Microorganism, n (%) Microorganism, n (%)
E. coli 120 (63) 147 (72) 61 (37) E. coli 231 (20) 353 (35) 263 (20)
Klebsiella spp 17 (9) 12 (6) 17 (10) Staphylococcus aureus 117 (10) 85 (9) 286 (21)
ESBL 18 (10) 4 (2) 9 (6) MRSA (of all Staphylococcus aureus
isolation)
42 (36) 10 (12) 186 (65)
Pseudomonas aeruginosa 10 (5) 5 (2) 19 (12) Klebsiella pneumoniae 85 (7) 48 (5) 180 (13)
Proteus spp. 8 (4) 14 (7) 12 (7) ESBL 21 (2) 14 (1) 61 (5)
Other gram negative rods 7 (4) 11 (5) 17 (10) Pseudomonas aeruginosa 58 (5) 20 (2) 121 (9)
Enterococcus spp. 8 (4) 7 (3) 12 (7) Streptococcus pneumoniae 21 (2) 132 (13) 15 (1)
PDR pathogensa, p value* 29 (15) 11 (5), p = 0.001 32 (20), p = 0.353 PDR pathogensa, p value* 132 (11) 49 (5), p < 0.0001 423 (32), p < 0.0001
*p value refers to comparison of HCAI with CAI or HCAI with HAI
aPDR pathogens = MRSA, Pseudomonas sp, Acinectobacter sp, Stenotrophomonas maltophilia, ESBL
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Two studies addressed urinary tract infection, both ori-
ginating from small, single centres [6, 22], and described
different microbiological profiles according to place of
acquisition, but showing no significant differences in the
prevalence of PDR pathogens by place of acquisition of
infection (Additional file 2: Table S1c, Table 1 and Fig. 2).
One small single centre study described the microbio-
logical profile of intra-abdominal infections [22], includ-
ing significant differences between the microbiological
profile of HCAI and CAI (p = 0.015), and HCAI and HAI
(p = 0.008), but included only a small number of patients
with microbiologically documented infection (Additional
file 2: Table S1d and Fig. 2).
Bloodstream HCAI also showed a microbiological pro-
file different between CAI and HAI (Additional file 2:
Table S1e, Table 1 and Fig. 2). The proportion of PDR
pathogens was 5 % in CAI, 11 % in HCAI and 32 % in
HAI (p < 0.001). Among the included studies, none pro-
vided a microbiological description of primary bacteremia.
The pooled OR (95 % CI) for infection by a PDR patho-
gen, in bloodstream infections, was 2.5 (1.3–4.8) for HCAI
when compared to CAI (I2 = 56 %, p = 0.04) (Fig. 2).
Accuracy of HCAI definition to predict infection by a PDR
pathogen
The overall sensitivity of HCAI definition to predict
infection by a PDR pathogen was 0.69 (0.65–0.72) and
the associated specificity was 0.67 (0.66–0.68), with an
I2test of 65 and 98 % respectively (Fig. 4).
The pooled positive likelihood ratio (LR) was 1,9 and
the pooled negative LR was 0,53, with an I2 test of 92
and 72 %, respectively (Fig. 5).
The area under the summary ROC curve was 0.71
(Fig. 6).
Risk of bias
Of the included studies, eight presented “low”, four
“moderate” and eight “high risk of bias” (Additional file
3: Table S2).
The analysis of the funnel plot shows asymmetry in
the lower left quadrant. This may reflect a lack of small
studies demonstrating a negative association of HCAI
and infection by PDR pathogens or eventually an over-
representation of positive studies.
Discussion
HCAI represented more than a third of all patients
admitted from the community setting into hospital care.
Patients with HCAI presented different microbiological
profiles when compared with community and hospital-
acquired infections for the major foci of infection: respira-
tory, endocarditis, urinary, intra-abdominal and blood-
stream infections.
Unfortunately only for pneumonia a fair number of
epidemiological studies were found allowing a very good
description of the microbiological profile involved, which
is the only HCAI for which specific treatment recom-
mendations are available [13] and they recommend
broad spectrum antibiotics with an empiric coverage of
Fig. 3 Association of HCAP with infection by PDR pathogens compared with CAP, according to geographic location.
Abbreviations: CAP, Community-acquired pneumonia; HCAP, healthcare-associated pneumonia; PDR – potentially drug resistant; CI, confidence interval;
M-H, Maentel-Haentzel
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Pseudomonas spp. and MRSA. In this review, Pseudo-
monas aeruginosa was present in only 10 % and MRSA
in 7 % of all microbiologically documented HCAP. If
these guidelines were used in this group of more than
1000 patients, over 70 % would receive overtreatment,
which is a well-known factor for the development and
increasing rate of multidrug resistance [29]. On the other
hand, the application of CAP treatment guidelines would
guarantee adequate antibiotic therapy in only 73 % of the
patients with microbiologic documentation of infection.
The use of piperacillin-tazobactam or aztreonam plus
azithromycin would increase the rate of adequate anti-
biotic therapy to 90 %, without creating such large un-
necessary microbiologic pressure.
It is possible that a narrower antibiotic spectrum
might be appropriate in specific groups of patients, such
as those without severe sepsis/septic shock and those
without immunosuppression, but the studies included in
this review did not provide data to address these items.
Nursing home-acquired (NHAP) pneumonia is the sub-
group of HCAI more studied: patients with non-severe
disease have a pathogen distribution similar to those
expected in CAP [30] and among patients with severe
NHAP (that is with organ dysfunction), resistant patho-
gens have been seen [10, 30, 31], suggesting that severity
of acute illness plays a role in the MDR prevalence. The
use of CAP guidelines treatment in non-severe NHAP is
supported by the study by El Solh et al. [32] that
Fig. 5 Positive and negative likelihood ratios (LR) for each study included in the analysis.
Abbreviations: CI, confidence interval; LR, likelihood ratio
Fig. 4 Sensitivity and specificity of HCAI definition to predict infection by potentially drug resistant pathogens.
Abbreviations: CI, confidence interval; HCAI, healthcare-associated infection
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reported no impact in clinical outcomes between those
patients treated according to the HCAP vs. the CAP
algorithm. These findings are also supported by the
study from Labelle et al. [33] where the use of CAP
guidelines to treat culture negative non-severe HCAP
was shown to be successful and the study by Attridge et
al. [34] where the treatment of non-severe HCAP
patients, with guideline concordant HCAP therapy was
not associated with improved survival compared with
guideline concordant CAP therapy (in fact it was associ-
ated with increased mortality). Thus, if one starts with a
broad spectrum HCAP regimen and by day 3 no micro-
biologic data exist to facilitate de-escalation clinicians
can feel comfortable narrowing the antimicrobial therapy
to no more than a CAP like regimen, particularly in
non-severe HCAP.In endocarditis, two studies were ana-
lysed [5, 28]: the first one included few patients and had
a “moderate risk of bias”; the second one [5] included a
significant number of patients but the exclusion of intra-
venous drug users and patients with prosthetic valves
probably deviated the predicted profile to show a lower
rate of Staphylococci spp., including MRSA, thus pre-
venting generalisation of the findings.
Regarding urinary tract and intra-abdominal infections
the inclusion of few, small studies with few patients,
prevents firm conclusions and generalisation. Clearly
larger, multicentre studies, designed towards microbio-
logical characterisation are needed.
The six studies on bloodstream infections gathered a
considerable number of patients, with similar propor-
tions of patients in the three groups. However, in order
to discuss empiric antibiotic therapy, it is necessary to
consider the microbiological profile of primary BSI and
none of the studies mention this. In fact only two studies
[22, 35] described the proportion of primary BSI by
place of acquisition, but still without describing the
microorganisms involved.
The lack of good quality studies regarding different
focus apart from pneumonia prevented an accurate de-
scription of the expected microbiologic profile for each
of the major focus of infection. Further studies on endo-
carditis, urinary, intra-abdominal and bloodstream infec-
tions are needed focusing on detailed microbiologic
profile involved in CAI, HCAI and HAI, to confirm the
utility of maintaining HCAI category to influence anti-
biotic prescription.
All studies included in this review used Deborah
Friedman’s HCAI definition [1] and showed an association
of HCAI with infection by a PDR organism that was
significant in the vast majority. Unfortunately, interpret-
ation of the summary measures was not possible due to
the associated medium-high heterogeneity (I2test > 50 %).
The discrimination power of the adopted HCAI definition
to predict infection by a PDR pathogen was fair, translated
by an AU-sROC curve of 0.71 (Fig. 6), which is in accord-
ance with a recent systematic review and meta-analysis
on the accuracy of HCAP definition to identify poten-
tially resistant pathogens [15]. The HCAP definition
adopted by the authors was the one proposed by ATS/
IDSA [13], but only five of the included studies met
that definition [24, 31, 36–38]; the additional 19 stud-
ies used different definitions (some of them included
Fig. 6 Discriminative power of HCAI definition to predict infection by PDR pathogens.
Abbreviations: HCAI, healthcare-associated infection; PDR, potentially drug resistant; ROC – receiver operating curve
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immunosuppression) [7, 39] and the majority [10, 25, 26,
40–45] used the definition proposed by Friedman et al.
[1]. The nine studies that used the definition by Friedman
et al. [1] were also included in the current review. Again
in that review all studies included showed an association
of HCAP with infection by a PDR pathogen.
In the 2011 European guidelines on adult respiratory
tract infections [16], the task force stated that although
the term HCAP has been putted forward after the 2005
publication of the ATS guidelines [13], evidence base did
not support the use of this term as being clinically rele-
vant in Europe at the time. The task force pointed 15
studies as evidence for this statement: two are part of
the current systematic review [10, 43], two used different
definitions of HCAP [7, 46], seven were on nursing
home community-acquired pneumonia [47–53], one on
Staphylococcus aureus pneumonia [54] and the rest did
not present any data on microbiology and/or comparison
with CAP microbiology [55–57]. The studies mentioned
in the guidelines that used a clear definition of HCAP and
compare the microbiology findings with CAP all show an
association of HCAP definition with infection by a PDR
pathogen [7, 10, 43, 46], which does not support the initial
statement of the task force.
The results of the current review reinforce the asso-
ciation of HCAI definition with infection by PDR
pathogens, the fact that it is not translated in good
discrimination power could be explained by the high het-
erogeneity of the studies included in the review. Also the
diverse criteria included in the definition might explain
part of this heterogeneity. A study focusing on the individ-
ual components of HCAI definitions is needed to deter-
mine the associated weight of each risk factor with an
infection by a MDR pathogen, to further stratify patients
in different levels of risk of infection by a MDR pathogen,
prompting different antibiotic recommendations accord-
ing to the predetermined risk, saving broad spectrum
antibiotic schemes for those patients with high risk, and
treating the rest with the narrower spectrum possible,
which will probably be the same as CAP for the low risk
patients.
The prevalence of PDR pathogens among patients
admitted to the hospital, from the community, with
pneumonia (either CAP or HCAP) is higher in Asia,
but the association of infection by a PDR pathogen
with HCAP (measured by the OR) was similar to that
found in Europe. This association was independent of
quality of included studies (either overall or considering
only “low risk of bias” studies) reinforcing the mainten-
ance of the three categories: community, healthcare-
associated and hospital-acquired pneumonia, in its
classification.
This review encountered several limitations. Firstly
retrospective cohort studies had to be included, which
might have limited the quality of clinical and microbio-
logical data and information.
Secondly, the rightful use of a strict case definition
allowed pooling of the results from different studies,
however the wide heterogeneity in the definitions of
HCAI used in published studies led to the exclusion of
many studies from other parts of the world that might
have shown different results. The HCAI definition [1]
chosen followed the findings of a recent systematic
review [3] that show that it is the most frequently used
definition in clinical research.
Thirdly, substantial heterogeneity between studies was
detected, which prevents the strict adoption of the
summary measure; this heterogeneity was independent
of the geographic area, overall quality of studies and
focus of infection. Using a more homogeneous popula-
tion would solve this, but would cause selection bias.
Fourthly, publication bias was detected. Studies with
positive findings are more likely to be published, but
after having researched references from reports, abstract
books and CD-ROMs from related scientific meetings,
places where negative findings are more likely to be
reported, it was concluded that these might have been
reported, but never published.
Fifth, despite the exhaustive bibliographic search de-
scribed and preformed there is always the possibility
of missing studies that could have met the inclusion
criteria.
This review also has several strengths: the research
method was exhaustive, leading to a huge number of
retrieved studies and a very long process of selection;
this type of sensitive electronic search was conducted in
several databases, including relevant conference pro-
ceedings and a manual search of additional sources,
which ensures that no relevant study was excluded.
The permissive criteria for study inclusion in this
review were essential to achieve the main goal: gathering
all studies on HCAI that provided a detailed microbiol-
ogy profile by focus of infection.
The careful selection of studies using exactly the same
definition of HCAI, CAI and HAI minimises the bias
related to overlapping categories and allows a proper
comparison between studies and summing of the results
found. This has been the major limitation of other
studies and consensus, which have used and pooled
results of studies using an heterogeneous set of defi-
nitions that preclude and bias pooled results and con-
clusions [15, 16].
The isolation rate was high (78 %), that is partially due
to the focus of infection included in the analysis: endo-
carditis and bloodstream infection that are dependent
on microbiology identification for diagnosis and urinary
tract infection that are also highly dependent on micro-
biologic documentation; even in HCAP microbiologic
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documentation of infection was possible in more than
half of the cases, so we believe that the described profile
are representative of the all cohort.
The majority of included studies were considered of
moderate or high quality considering the simplicity of
the evaluation. The criteria used were based on the
STROBE Statement: clear definition of inclusion criteria
and selection method, consecutive selection of patients,
and no attrition or reporting bias. Considering the found
of observational studies the researchers think that those
are the most adequate criteria to evaluate risk of bias in
this type of studies. Although this is a very relevant
analysis, the fact is that we found no major differences
among studies depending on their methodological quality.
Conclusions
This systematic review provides evidence that HCAI is
significantly different from CAI and HAI, representing a
separate group of infections in terms of the microbiology
profile, including a significant association with infection
by PDR pathogens, for the main focus of infection.
An accurate microbiological characterization of HCAI
was not possible for the main focus of infection apart
from pneumonia due to the lack of good epidemiological
studies in this area.
The accuracy of Friedman et al. HCAI definition for
predicting infection by PDR pathogens was fair, but all
studies included showed a consistent association of HCAI
with infection by PDR.
The pursue of good epidemiological studies is of
the utmost relevance to allow a good microbiological
characterization of HCAI for the main focus of infec-
tion helping the clinician in the selection of empiric
antibiotic therapy and international societies in the
development of specific treatment recommendations.
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